Anteris Reports FY25 SG&A Expenses of $26.1M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 5 days ago
0mins
Should l Buy AVR?
Reports FY25 SG&A expenses $26.1M. "2025 was a pivotal year for Anteris, advancing DurAVR with disciplined execution, strengthening our clinical foundation, and positioning the company for long term leadership in structural heart. We converted strategy into measurable progress, reinforcing our competitive position and accelerating our path toward commercial readiness. The progress achieved in 2025 has strengthened our foundation and sharpened our trajectory toward becoming a leader in next-generation TAVR. We remained focused on what matters most; advancing clinical evidence, strengthening our balance sheet, and building sustainable long-term value," said Wayne Paterson, Vice Chairman and Chief Executive Officer of Anteris.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy AVR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on AVR
Wall Street analysts forecast AVR stock price to rise
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 6.620
Low
15.00
Averages
17.33
High
22.00
Current: 6.620
Low
15.00
Averages
17.33
High
22.00
About AVR
Anteris Technologies Global Corp. is a structural heart company, which is engaged in providing cardiac care by science-driven and measurable advancements to restore heart valve patients to healthy function. Its lead asset, the DurAVR Transcatheter Heart Valve System (THV) consists of a single-piece, biomimetic valve made with its ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. DurAVR THV is a novel transcatheter aortic valve for the treatment of aortic stenosis that is shaped to mimic the performance of a healthy human aortic valve. DurAVR THV’s single-piece design mimics the native anatomy of a human aortic valve, as compared to traditional three-piece aortic valves. The Company’s ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold. Its ComASUR delivery system is a physician-developed balloon expandable delivery system.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Anteris Technologies Reports FY Financials and Public Offering
- Cash Outflow Situation: For the fiscal year ending December 31, 2025, Anteris Technologies reported net operating cash outflows of $77.8 million, primarily driven by increased clinical, regulatory, and manufacturing demands, indicating a significant investment in the PARADIGM Trial.
- Public Offering Plan: Anteris Technologies announced a $200 million public offering alongside a $90 million placement with Medtronic, aimed at securing funding for future R&D and operations, thereby enhancing its competitive position in the market.
- Clinical Trial Demands: As the PARADIGM Trial progresses, the company faces escalating clinical and regulatory requirements, which not only impact cash outflows but may also influence future financing strategies and market performance.
- Market Reaction Expectations: Despite the high cash outflow pressures, Anteris Technologies is expected to achieve greater financial stability and business growth through successful fundraising efforts, positioning itself favorably in the evolving healthcare landscape.
See More
Anteris Technologies Reports 2025 Financial Results and Updates
- Clinical Trial Launch: Anteris initiated the global pivotal PARADIGM Trial in 2025, building on the successful treatment of 130 patients, aiming to evaluate the safety and efficacy of DurAVR®THV, thereby establishing a foundation for the company's leadership in structural heart disease.
- FDA Approval Progress: The company received FDA Investigational Device Exemption approval in Q4 2025 to conduct the PARADIGM Trial in the U.S., which will accelerate clinical activities and enhance market competitiveness.
- Financial Performance: In 2025, Anteris reported net operating cash outflows of $77.8 million, primarily to support clinical, regulatory, and manufacturing needs for the PARADIGM Trial, reflecting the company's ongoing investment in R&D and market readiness.
- Successful Capital Raise: Anteris completed a total capital raise of $320 million in early 2026, including a strategic investment from Medtronic, which will support the execution of the PARADIGM Trial and advance the global commercialization of the DurAVR®THV System.
See More
Anteris Technologies to Present at Major Healthcare Conferences
- Conference Participation: Anteris Technologies' Vice Chairman and CEO Wayne Paterson will present at the TD Cowen and Barclays Healthcare Conferences on March 2 and March 10, 2026, respectively, showcasing the company's advancements in structural heart disease, which is expected to attract investor interest.
- Webcast Access: The TD Cowen conference webcast will start at 3:10 PM EST on March 2, while the Barclays conference will begin at 1:30 PM EST on March 10, both accessible via the company's Investor Center on its website, ensuring real-time information for investors.
- Product Overview: Anteris' flagship product, the DurAVR® Transcatheter Heart Valve (THV), utilizes FDA-cleared ADAPT® tissue technology and has been used in over 55,000 patients globally, aimed at treating aortic stenosis, demonstrating the company's innovative capabilities in cardiac medical devices.
- Market Outlook: By participating in these significant healthcare conferences, Anteris Technologies not only enhances its brand visibility but also strengthens relationships with investors, thereby laying the groundwork for future capital raising and market expansion.
See More
Anteris Technologies (AVR) Secures $320M Financing, Price Target Cut to $15
- Financing Impact: Anteris Technologies successfully secured $320 million in financing, including a $90 million strategic investment from Medtronic, which the analyst describes as a 'transformational deal' that will significantly improve the company's capital structure.
- Price Target Adjustment: Lake Street analyst Frank Takkinen lowered Anteris' price target from $20 to $15, primarily due to the dilutive impact of the financing, yet maintains a 'Buy' rating, reflecting confidence in the company's future prospects.
- Strengthened Collaboration: This financing not only alleviates capital overhang but also verifies product viability and solidifies the collaboration with Medtronic, which may become a potential acquirer, enhancing Anteris' market position.
- Market Outlook: The analyst notes that the financing will support Anteris' PARADIGM trial, expected to drive further development in the cardiovascular sector, thereby enhancing its competitiveness in the industry.
See More
Anteris Technologies (AVR) Closes $40 Million Public Offering
- Funding Size: Anteris Technologies successfully closed a $40 million public offering, strengthening its capital base to support future R&D and market expansion.
- Market Reaction: The completion of this offering signifies the company's stable performance in the capital markets, expected to boost investor confidence and provide funding for subsequent projects.
- Strategic Importance: Through this offering, Anteris aims to accelerate its innovation in cardiovascular treatments, further solidifying its market position.
- Future Outlook: The company plans to utilize the raised funds to advance clinical trials and expand its product line, addressing the growing market demand and enhancing competitiveness.
See More
ANTERIS TECHNOLOGIES STOCK RISES 8.7% FOLLOWING $200 MILLION STOCK OFFERING AND MEDTRONIC INVESTMENT ANNOUNCEMENT
- Stock Performance: Anteris Technologies shares increased by 8.7% following the announcement of a $200 million stock offering.
- Investment Focus: The company is focusing on Medtronic investment opportunities as part of its strategic financial moves.
See More
Anteris Technologies Reports FY Financials and Public Offering
- Cash Outflow Situation: For the fiscal year ending December 31, 2025, Anteris Technologies reported net operating cash outflows of $77.8 million, primarily driven by increased clinical, regulatory, and manufacturing demands, indicating a significant investment in the PARADIGM Trial.
- Public Offering Plan: Anteris Technologies announced a $200 million public offering alongside a $90 million placement with Medtronic, aimed at securing funding for future R&D and operations, thereby enhancing its competitive position in the market.
- Clinical Trial Demands: As the PARADIGM Trial progresses, the company faces escalating clinical and regulatory requirements, which not only impact cash outflows but may also influence future financing strategies and market performance.
- Market Reaction Expectations: Despite the high cash outflow pressures, Anteris Technologies is expected to achieve greater financial stability and business growth through successful fundraising efforts, positioning itself favorably in the evolving healthcare landscape.
See More
Anteris Technologies Reports 2025 Financial Results and Updates
- Clinical Trial Launch: Anteris initiated the global pivotal PARADIGM Trial in 2025, building on the successful treatment of 130 patients, aiming to evaluate the safety and efficacy of DurAVR®THV, thereby establishing a foundation for the company's leadership in structural heart disease.
- FDA Approval Progress: The company received FDA Investigational Device Exemption approval in Q4 2025 to conduct the PARADIGM Trial in the U.S., which will accelerate clinical activities and enhance market competitiveness.
- Financial Performance: In 2025, Anteris reported net operating cash outflows of $77.8 million, primarily to support clinical, regulatory, and manufacturing needs for the PARADIGM Trial, reflecting the company's ongoing investment in R&D and market readiness.
- Successful Capital Raise: Anteris completed a total capital raise of $320 million in early 2026, including a strategic investment from Medtronic, which will support the execution of the PARADIGM Trial and advance the global commercialization of the DurAVR®THV System.
See More
Anteris Technologies to Present at Major Healthcare Conferences
- Conference Participation: Anteris Technologies' Vice Chairman and CEO Wayne Paterson will present at the TD Cowen and Barclays Healthcare Conferences on March 2 and March 10, 2026, respectively, showcasing the company's advancements in structural heart disease, which is expected to attract investor interest.
- Webcast Access: The TD Cowen conference webcast will start at 3:10 PM EST on March 2, while the Barclays conference will begin at 1:30 PM EST on March 10, both accessible via the company's Investor Center on its website, ensuring real-time information for investors.
- Product Overview: Anteris' flagship product, the DurAVR® Transcatheter Heart Valve (THV), utilizes FDA-cleared ADAPT® tissue technology and has been used in over 55,000 patients globally, aimed at treating aortic stenosis, demonstrating the company's innovative capabilities in cardiac medical devices.
- Market Outlook: By participating in these significant healthcare conferences, Anteris Technologies not only enhances its brand visibility but also strengthens relationships with investors, thereby laying the groundwork for future capital raising and market expansion.
See More
Anteris Technologies (AVR) Secures $320M Financing, Price Target Cut to $15
- Financing Impact: Anteris Technologies successfully secured $320 million in financing, including a $90 million strategic investment from Medtronic, which the analyst describes as a 'transformational deal' that will significantly improve the company's capital structure.
- Price Target Adjustment: Lake Street analyst Frank Takkinen lowered Anteris' price target from $20 to $15, primarily due to the dilutive impact of the financing, yet maintains a 'Buy' rating, reflecting confidence in the company's future prospects.
- Strengthened Collaboration: This financing not only alleviates capital overhang but also verifies product viability and solidifies the collaboration with Medtronic, which may become a potential acquirer, enhancing Anteris' market position.
- Market Outlook: The analyst notes that the financing will support Anteris' PARADIGM trial, expected to drive further development in the cardiovascular sector, thereby enhancing its competitiveness in the industry.
See More
Anteris Technologies (AVR) Closes $40 Million Public Offering
- Funding Size: Anteris Technologies successfully closed a $40 million public offering, strengthening its capital base to support future R&D and market expansion.
- Market Reaction: The completion of this offering signifies the company's stable performance in the capital markets, expected to boost investor confidence and provide funding for subsequent projects.
- Strategic Importance: Through this offering, Anteris aims to accelerate its innovation in cardiovascular treatments, further solidifying its market position.
- Future Outlook: The company plans to utilize the raised funds to advance clinical trials and expand its product line, addressing the growing market demand and enhancing competitiveness.
See More
ANTERIS TECHNOLOGIES STOCK RISES 8.7% FOLLOWING $200 MILLION STOCK OFFERING AND MEDTRONIC INVESTMENT ANNOUNCEMENT
- Stock Performance: Anteris Technologies shares increased by 8.7% following the announcement of a $200 million stock offering.
- Investment Focus: The company is focusing on Medtronic investment opportunities as part of its strategic financial moves.
See More
